原発性卵巣不全症の世界市場レポート 2025年

原発性卵巣不全症の市場規模は今後数年で急成長が見込まれます。2029年には年間平均成長率（CAGR）10.0％で17億3,000万米ドルに成長します。予測期間中、生殖補助医療技術の利用拡大、妊孕性温存オプションの採用拡大、個別化医療への注目の高まり、ホルモン療法の人気上昇、妊孕性温存技術の利用拡大が成長を牽引すると予想されます。この期間の主な動向としては、診断技術の発展、遺伝子検査の統合、妊孕性温存の革新、非ホルモン療法の開発、早期発見バイオマーカーの進歩などが挙げられます。

自己免疫疾患の有病率の増加は、原発性卵巣不全症（POI）市場の成長を促進すると予想されます。自己免疫疾患は、免疫系が誤って体内の健康な細胞や組織を攻撃し、損傷することで発生します。自己免疫疾患の増加は主に遺伝的素因に起因しており、免疫系の機能不全に陥りやすくなる特定の遺伝子を受け継いでいます。原発性卵巣不全症（POI）は、ホルモンバランスの乱れと免疫システムの調節不全がどのように相互作用し、罹患者において自己免疫疾患のリスクが高まるかを示すことにより、自己免疫疾患に関する洞察を提供することができます。例えば、2024年11月、ドイツを拠点とする組織であるVersorgungsatlas.deは、2022年に7,324万1,305人の被保険者のうち、630万4,340人が少なくとも1つの自己免疫疾患と診断され、有病率は8.61％であったと報告しています。したがって、自己免疫疾患の有病率の増加が原発性卵巣不全症市場の成長に寄与しています。

原発性卵巣不全症市場の主要企業は、卵巣機能を回復させ不妊治療成績を改善するために、同種エキソソーム療法などの革新的な治療法の開発に注力しています。同種エクソソーム療法は、ドナー幹細胞由来の細胞外小胞（エクソソーム）を用いて、POI患者の組織修復を促進し卵巣機能を回復させる再生シグナルを送達します。例えば、2022年10月、米国のバイオテクノロジー企業であるVitti Labs LLCは、原発性卵巣不全症の治療薬であるEV-Pureの承認を米国食品医薬品局（FDA）から取得しました。この治療薬は、間葉系間質細胞由来のエクソソームの再生、免疫調節、抗炎症特性を活用し、卵巣機能と生殖能力を回復させる。この治療法は、悪性化や免疫拒絶などの細胞ベースの治療に伴うリスクを回避する一方で、組織の修復と恒常性を促進する生物活性分子を送達する、既製の無細胞ソリューションを提供します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の原発性卵巣不全症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の原発性卵巣不全症市場：成長率分析
• 世界の原発性卵巣不全症市場の実績：規模と成長, 2019-2024
• 世界の原発性卵巣不全症市場の予測：規模と成長, 2024-2029, 2034F
• 世界の原発性卵巣不全症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の原発性卵巣不全症市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ホルモン補充療法（HRT）
• カルシウムとビタミンDのサプリメント
• 体外受精（IVF）
• 幹細胞療法
• その他のタイプ
• 世界の原発性卵巣不全症市場：診断方法別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血液検査
• 超音波画像診断
• 遺伝子検査
• 世界の原発性卵巣不全症市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 20歳未満
• 20～30歳
• 30歳から45歳
• 45歳以上
• 世界の原発性卵巣不全症市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 専門不妊治療センター
• 世界の原発性卵巣不全症市場、ホルモン補充療法、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• エストロゲン療法
• エストロゲン・プロゲスチン療法
• 経皮パッチ
• 膣エストロゲン製品
• 経口ホルモン療法
• 世界の原発性卵巣不全症市場、カルシウムとビタミンDサプリメント、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• 炭酸カルシウム
• クエン酸カルシウム
• ビタミンD2（エルゴカルシフェロール）
• ビタミンD3（コレカルシフェロール）
• カルシウムとビタミンDの配合
• 世界の原発性卵巣不全症市場、体外受精、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• 従来の体外受精
• 卵細胞質内精子注入法（ICSI）
• 卵子提供体外受精
• 胚の凍結と移植
• 着床前遺伝子検査（PGT）
• 世界の原発性卵巣不全症市場、幹細胞療法、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• 自家幹細胞療法
• 同種幹細胞療法
• 間葉系幹細胞（MSC）療法
• 卵巣幹細胞移植
• 世界の原発性卵巣不全症市場、その他のタイプ、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• 心理カウンセリングとサポート療法
• 生殖補助医療
• 免疫調節療法
• ライフスタイルと食事介入

第7章 地域別・国別分析

• 世界の原発性卵巣不全症市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の原発性卵巣不全症市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 原発性卵巣不全症市場：競合情勢
• 原発性卵巣不全症市場：企業プロファイル
  • Mayo Clinic Overview, Products and Services, Strategy and Financial Analysis
  • Johns Hopkins Medicine Overview, Products and Services, Strategy and Financial Analysis
  • Baptist Health Overview, Products and Services, Strategy and Financial Analysis
  • Ferring Pharmaceuticals A/S Overview, Products and Services, Strategy and Financial Analysis
  • The Kingsley Natural Health Clinic Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• PreventionGenetics LLC
• The Fertility Partnership（TFP）UK
• Celmatix Inc.
• European Society of Human Reproduction and Embryology（ESHRE）
• Endocrine Society
• IVIRMA Global
• American Society for Reproductive Medicine（ASRM）
• TCM Healthcare（UK）Ltd.
• Bioscience Institute S.p.A.
• Sparsh Diagnostics Pvt. Ltd.
• Welling Homeopathy Clinics Pvt. Ltd.
• Bristol Menopause Clinic
• Indira IVF Hospital Private Limited
• Lawley Pharmaceuticals Pty. Ltd.
• OvaScience Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 原発性卵巣不全症市場2029：新たな機会を提供する国
• 原発性卵巣不全症市場2029：新たな機会を提供するセグメント
• 原発性卵巣不全症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Primary ovarian insufficiency (POI) is a condition in which the ovaries stop functioning properly before the age of 40, leading to reduced estrogen production and irregular or absent menstrual periods. This condition can result in infertility and is often linked to hormonal imbalances, even though some ovarian activity may still be present.

The main treatments for primary ovarian insufficiency include hormone replacement therapy (HRT), calcium and vitamin D supplements, in vitro fertilization (IVF), stem cell therapy, and other options. Hormone replacement therapy (HRT) involves supplementing hormones, typically estrogen and progesterone, to alleviate symptoms caused by hormonal imbalances or deficiencies, particularly during menopause. Diagnostic methods for POI include blood tests, ultrasound imaging, and genetic testing. This condition can affect individuals across different age groups, including those under 20, 20 to 30 years old, 30 to 45 years old, and those over 45. The treatments are used by various end users, such as hospitals, clinics, and specialized fertility centers.

The primary ovarian insufficiency market research report is one of a series of new reports from The Business Research Company that provides primary ovarian insufficiency market statistics, including the primary ovarian insufficiency industry's global market size, regional shares, competitors with the primary ovarian insufficiency market share, detailed primary ovarian insufficiency market segments, market trends and opportunities, and any further data you may need to thrive in the primary ovarian insufficiency market. This primary ovarian insufficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The primary ovarian insufficiency market size has grown rapidly in recent years. It will grow from $1.07 billion in 2024 to $1.18 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth during the historic period can be attributed to factors such as the increasing prevalence of autoimmune disorders, rising stress levels, a higher incidence of genetic mutations, a growing number of women delaying childbirth, and a rising prevalence of endocrine disorders.

The primary ovarian insufficiency market size is expected to see rapid growth in the next few years. It will grow to $1.73 billion in 2029 at a compound annual growth rate (CAGR) of 10.0%. In the forecast period, growth is expected to be driven by the growing use of assisted reproductive technologies, increased adoption of fertility preservation options, a stronger focus on personalized medicine, rising popularity of hormonal therapies, and a greater use of fertility preservation techniques. Key trends during this period include advancements in diagnostic technologies, the integration of genetic testing, innovations in fertility preservation, the development of non-hormonal therapies, and progress in early detection biomarkers.

The increasing prevalence of autoimmune disorders is expected to drive the growth of the primary ovarian insufficiency (POI) market. Autoimmune disorders occur when the immune system mistakenly attacks and damages the body's own healthy cells and tissues. The rise in autoimmune disorders is primarily attributed to genetic predisposition, where individuals inherit certain genes that make them more vulnerable to immune system malfunctions. Primary ovarian insufficiency (POI) can provide insights into autoimmune disorders by showing how hormonal imbalances and immune system dysregulation interact, leading to a heightened risk of autoimmune diseases in affected individuals. For instance, in November 2024, Versorgungsatlas.de, a Germany-based organization, reported that in 2022, out of 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, reflecting a prevalence rate of 8.61%. Therefore, the increasing prevalence of autoimmune disorders is contributing to the growth of the primary ovarian insufficiency market.

Leading companies in the primary ovarian insufficiency market are focusing on developing innovative therapies, such as allogenic exosomal therapy, to restore ovarian function and improve fertility outcomes. Allogenic exosomal therapy uses extracellular vesicles, or exosomes, derived from donor stem cells to deliver regenerative signals that promote tissue repair and restore ovarian function in patients with POI. For example, in October 2022, Vitti Labs LLC, a US-based biotechnology company, received approval from the US Food and Drug Administration (FDA) for EV-Pure, a treatment for primary ovarian insufficiency. This therapy leverages the regenerative, immunomodulatory, and anti-inflammatory properties of mesenchymal stromal cell-derived exosomes to restore ovarian function and fertility. It provides an off-the-shelf, cell-free solution that avoids the risks associated with cell-based treatments, such as malignant transformation or immune rejection, while delivering bioactive molecules to promote tissue repair and homeostasis.

In July 2023, EQT Private Capital Asia, a China-based investment company, acquired a 60% stake in Indira IVF Hospital Pvt. Ltd. for \$1.1 billion. This acquisition aims to expand Indira IVF's market leadership in India and Asia, enhance its technological capabilities, and scale operations to take advantage of the rapidly growing fertility services market. Indira IVF Hospital Pvt. Ltd. is a fertility clinic based in India that specializes in the diagnosis and treatment of primary ovarian insufficiency (POI), also known as premature ovarian failure (POF).

Major players in the primary ovarian insufficiency market are Mayo Clinic, Johns Hopkins Medicine, Baptist Health, Ferring Pharmaceuticals A/S, The Kingsley Natural Health Clinic, PreventionGenetics LLC, The Fertility Partnership (TFP) UK, Celmatix Inc., European Society of Human Reproduction and Embryology (ESHRE), Endocrine Society, IVIRMA Global, American Society for Reproductive Medicine (ASRM), TCM Healthcare (UK) Ltd., Bioscience Institute S.p.A., Sparsh Diagnostics Pvt. Ltd., Welling Homeopathy Clinics Pvt. Ltd., Bristol Menopause Clinic, Indira IVF Hospital Private Limited, Lawley Pharmaceuticals Pty. Ltd., OvaScience Inc.

North America was the largest region in the primary ovarian insufficiency market in 2024. The regions covered in primary ovarian insufficiency report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the primary ovarian insufficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary ovarian insufficiency market consists of revenues earned by entities by providing services such as fertility treatments, diagnostic and genetic testing services, osteoporosis management services, and endocrinology consultation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary ovarian insufficiency market also consists of sales of products including genetic testing kits, bone health supplements, psychological and supportive care products, testosterone therapy, and antioxidant supplements. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Primary Ovarian Insufficiency Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on primary ovarian insufficiency market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for primary ovarian insufficiency ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The primary ovarian insufficiency market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Hormone Replacement Therapy (HRT); Calcium and Vitamin D Supplements; In Vitro Fertilization (IVF); Stem Cell Therapy; Other Types
• 2) By Diagnosis Method: Blood Tests; Ultrasound Imaging; Genetic Testing
• 3) By Application: Less Than 20 Years Old; 20 To 30 Years Old; 30 To 45 Years Old; 45 Years Old And Older
• 4) By End-Users: Hospitals And Clinics; Specialty Fertility Centers
• Subsegments:
• 1) By Hormone Replacement Therapy: Estrogen Therapy; Estrogen-Progestin Therapy; Transdermal Patches; Vaginal Estrogen Products; Oral Hormone Therapy
• 2) By Calcium And Vitamin D Supplements: Calcium Carbonate; Calcium Citrate; Vitamin D2 (Ergocalciferol); Vitamin D3 (Cholecalciferol); Combined Calcium + Vitamin D Formulations
• 3) By In Vitro Fertilization: Conventional In Vitro Fertilization; Intracytoplasmic Sperm Injection (ICSI); Egg Donation In Vitro Fertilization; Embryo Freezing And Transfer; Preimplantation Genetic Testing (PGT)
• 4) By Stem Cell Therapy: Autologous Stem Cell Therapy; Allogeneic Stem Cell Therapy; Mesenchymal Stem Cell (MSC) Therapy; Ovarian Stem Cell Transplantation
• 5) By Other Types: Psychological Counseling And Support Therapies; Assisted Reproductive Technologies (other than IVF); Immunomodulatory Therapies; Lifestyle And Dietary Interventions
• Companies Mentioned: Mayo Clinic; Johns Hopkins Medicine; Baptist Health; Ferring Pharmaceuticals A/S; The Kingsley Natural Health Clinic
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Primary Ovarian Insufficiency Market Characteristics

3. Primary Ovarian Insufficiency Market Trends And Strategies

4. Primary Ovarian Insufficiency Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Primary Ovarian Insufficiency Growth Analysis And Strategic Analysis Framework

• 5.1. Global Primary Ovarian Insufficiency PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Primary Ovarian Insufficiency Market Growth Rate Analysis
• 5.4. Global Primary Ovarian Insufficiency Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Primary Ovarian Insufficiency Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Primary Ovarian Insufficiency Total Addressable Market (TAM)

6. Primary Ovarian Insufficiency Market Segmentation

• 6.1. Global Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hormone Replacement Therapy (HRT)
• Calcium and Vitamin D Supplements
• In Vitro Fertilization (IVF)
• Stem Cell Therapy
• Other Types
• 6.2. Global Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Tests
• Ultrasound Imaging
• Genetic Testing
• 6.3. Global Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Less Than 20 Years Old
• 20 To 30 Years Old
• 30 To 45 Years Old
• 45 Years Old And Older
• 6.4. Global Primary Ovarian Insufficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Specialty Fertility Centers
• 6.5. Global Primary Ovarian Insufficiency Market, Sub-Segmentation Of Hormone Replacement Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Estrogen Therapy
• Estrogen-Progestin Therapy
• Transdermal Patches
• Vaginal Estrogen Products
• Oral Hormone Therapy
• 6.6. Global Primary Ovarian Insufficiency Market, Sub-Segmentation Of Calcium And Vitamin D Supplements, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Calcium Carbonate
• Calcium Citrate
• Vitamin D2 (Ergocalciferol)
• Vitamin D3 (Cholecalciferol)
• Combined Calcium + Vitamin D Formulations
• 6.7. Global Primary Ovarian Insufficiency Market, Sub-Segmentation Of In Vitro Fertilization, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Conventional In Vitro Fertilization
• Intracytoplasmic Sperm Injection (ICSI)
• Egg Donation In Vitro Fertilization
• Embryo Freezing And Transfer
• Preimplantation Genetic Testing (PGT)
• 6.8. Global Primary Ovarian Insufficiency Market, Sub-Segmentation Of Stem Cell Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autologous Stem Cell Therapy
• Allogeneic Stem Cell Therapy
• Mesenchymal Stem Cell (MSC) Therapy
• Ovarian Stem Cell Transplantation
• 6.9. Global Primary Ovarian Insufficiency Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Psychological Counseling And Support Therapies
• Assisted Reproductive Technologies
• Immunomodulatory Therapies
• Lifestyle And Dietary Interventions

7. Primary Ovarian Insufficiency Market Regional And Country Analysis

• 7.1. Global Primary Ovarian Insufficiency Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Primary Ovarian Insufficiency Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Primary Ovarian Insufficiency Market

• 8.1. Asia-Pacific Primary Ovarian Insufficiency Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Primary Ovarian Insufficiency Market

• 9.1. China Primary Ovarian Insufficiency Market Overview
• 9.2. China Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Primary Ovarian Insufficiency Market

• 10.1. India Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Primary Ovarian Insufficiency Market

• 11.1. Japan Primary Ovarian Insufficiency Market Overview
• 11.2. Japan Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Primary Ovarian Insufficiency Market

• 12.1. Australia Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Primary Ovarian Insufficiency Market

• 13.1. Indonesia Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Primary Ovarian Insufficiency Market

• 14.1. South Korea Primary Ovarian Insufficiency Market Overview
• 14.2. South Korea Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Primary Ovarian Insufficiency Market

• 15.1. Western Europe Primary Ovarian Insufficiency Market Overview
• 15.2. Western Europe Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Primary Ovarian Insufficiency Market

• 16.1. UK Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Primary Ovarian Insufficiency Market

• 17.1. Germany Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Primary Ovarian Insufficiency Market

• 18.1. France Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Primary Ovarian Insufficiency Market

• 19.1. Italy Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Primary Ovarian Insufficiency Market

• 20.1. Spain Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Primary Ovarian Insufficiency Market

• 21.1. Eastern Europe Primary Ovarian Insufficiency Market Overview
• 21.2. Eastern Europe Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Primary Ovarian Insufficiency Market

• 22.1. Russia Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Primary Ovarian Insufficiency Market

• 23.1. North America Primary Ovarian Insufficiency Market Overview
• 23.2. North America Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Primary Ovarian Insufficiency Market

• 24.1. USA Primary Ovarian Insufficiency Market Overview
• 24.2. USA Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Primary Ovarian Insufficiency Market

• 25.1. Canada Primary Ovarian Insufficiency Market Overview
• 25.2. Canada Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Primary Ovarian Insufficiency Market

• 26.1. South America Primary Ovarian Insufficiency Market Overview
• 26.2. South America Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Primary Ovarian Insufficiency Market

• 27.1. Brazil Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Primary Ovarian Insufficiency Market

• 28.1. Middle East Primary Ovarian Insufficiency Market Overview
• 28.2. Middle East Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Primary Ovarian Insufficiency Market

• 29.1. Africa Primary Ovarian Insufficiency Market Overview
• 29.2. Africa Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Primary Ovarian Insufficiency Market Competitive Landscape And Company Profiles

• 30.1. Primary Ovarian Insufficiency Market Competitive Landscape
• 30.2. Primary Ovarian Insufficiency Market Company Profiles
  • 30.2.1. Mayo Clinic Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johns Hopkins Medicine Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Baptist Health Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Ferring Pharmaceuticals A/S Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. The Kingsley Natural Health Clinic Overview, Products and Services, Strategy and Financial Analysis

31. Primary Ovarian Insufficiency Market Other Major And Innovative Companies

• 31.1. PreventionGenetics LLC
• 31.2. The Fertility Partnership (TFP) UK
• 31.3. Celmatix Inc.
• 31.4. European Society of Human Reproduction and Embryology (ESHRE)
• 31.5. Endocrine Society
• 31.6. IVIRMA Global
• 31.7. American Society for Reproductive Medicine (ASRM)
• 31.8. TCM Healthcare (UK) Ltd.
• 31.9. Bioscience Institute S.p.A.
• 31.10. Sparsh Diagnostics Pvt. Ltd.
• 31.11. Welling Homeopathy Clinics Pvt. Ltd.
• 31.12. Bristol Menopause Clinic
• 31.13. Indira IVF Hospital Private Limited
• 31.14. Lawley Pharmaceuticals Pty. Ltd.
• 31.15. OvaScience Inc.

32. Global Primary Ovarian Insufficiency Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Primary Ovarian Insufficiency Market

34. Recent Developments In The Primary Ovarian Insufficiency Market

35. Primary Ovarian Insufficiency Market High Potential Countries, Segments and Strategies

• 35.1 Primary Ovarian Insufficiency Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Primary Ovarian Insufficiency Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Primary Ovarian Insufficiency Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer